Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia

Cass, Samuel; Tobin, Joshua W.D.; Seo, Yongwoo David; Gener-Ricos, Georgina; Keung, Emily Z.; Burton, Elizabeth M.; Davies, Michael A.; McQuade, Jennifer L.; Lazar, Alexander J.; Mason, Robert M.; Millward, Michael; Sandhu, Shahneen; Khoo, Christine; Warburton, Lydia; Guerra, Veronica; Haydon, Andrew; Dearden, Helen; Menzies, A.M.; Carlino, Matteo S.; Smith, Jessica L.; Mollee, Peter; Burgess, Melinda; Mapp, Sally; Keane, Colm; Atkinson, Victoria; Markovic, Svetomir N.; Ding, Wei; Call, Timothy G.; Hampel, Paul J.; Long, Georgina V.; Wargo, Jennifer A.; Ferrajoli, Alessandra

doi:10.1016/j.annonc.2023.06.007

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before development of immune checkpoint receptor inhibitors (ICIs), there was a large difference in median survival between patients with melanoma alone compared to those with melanoma and CLL (91.4 months vs. 59.3 months, respectively) 70 . Studies investigating effect of ICIs (including nivolumab, pembrolizumab, and ipilimumab) on advanced melanoma in CLL patients indicate comparable objective response rates and PFS compared to patients without hematologic malignancy, although prior CLL treatment (particularly fludarabine) and high/intermediate risk CLL have been associated with poorer melanoma‐specific outcomes following checkpoint blockade 71–74 . ICIs have no demonstrated effect on CLL 75 …”

Section: Epidemiology Of Melanoma In Cll Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous malignancies in chronic lymphocytic leukemia

Zilberg,

Ferguson,

Lyons

et al. 2024

The Journal of Dermatology

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy that is associated with an increased risk of developing cutaneous malignancies. Clinical outcomes for these malignancies, including melanoma and keratinocyte cancers (KC), are worse for patients with CLL. Individuals with CLL develop an immunodeficiency of both the adaptive and innate immune system, which plays a role in the increased prevalence of skin cancers. This review focuses on the complex interplay between genetics, immunity, and pathogens that influence the cellular composition and biology of skin tumors and their microenvironment in CLL patients, and in comparison with other chronic hematological malignancies. It is paramount for dermatologists to be aware of the association between CLL (and chronic hematological malignancies more broadly) and cutaneous malignancies. This is a high‐risk population who require regular and vigorous dermatologic follow‐up.

show abstract

Section: Epidemiology Of Melanoma In Cll Patientsmentioning

confidence: 99%

“…with poorer melanoma-specific outcomes following checkpoint blockade. [71][72][73][74] ICIs have no demonstrated effect on CLL. 75 Melanoma is more prevalent in patients with CLL and other types of NHL.…”

Section: Epidemi Ology Of Mel Anoma In Cll Patientsmentioning

confidence: 99%

Cutaneous malignancies in chronic lymphocytic leukemia

Zilberg,

Ferguson,

Lyons

et al. 2024

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors

McLean,

Lim,

Angel

et al. 2024

Cancers

View full text Add to dashboard Cite

Non-melanomatous cutaneous spindle cell neoplasms are a rare group of malignancies that present a diagnostic challenge, and for which there is a lack of consensus on how to best manage patients with advanced disease and only limited reports of immune-checkpoint inhibitor (ICI) responses. In this study, we performed a single-center retrospective review of treatment outcomes for all advanced non-melanomatous cutaneous spindle cell neoplasms treated with ICIs. Blinded histopathology reviews occurred to confirm each diagnosis. Comprehensive tumour profiling included whole exome sequencing for tumour mutational burden (TMB) and ultraviolet(UV) signatures, and immunohistochemistry for immune-cell infiltration (CD4/CD3/CD8/CD103/CD20) and immune-checkpoint expression (PD-L1/LAG3/TIGIT). Seven patients were identified. The objective response rate was 86% (6/7) with five complete responses (CR). Responses were durable with two patients in CR > 30 months after ICI commencement. All patients had high TMB and UV signatures. One patient had PD-L1 100% (combined positive score) with abundant immune-cell infiltration and LAG3 expression. In advanced non-melanomatous cutaneous spindle cell neoplasms, excellent responses to ICIs with durable disease control were observed. ICIs are worthy of further exploration in these patients. UV signatures and high TMB could be used to help select patients for treatment.

show abstract

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia

Cited by 2 publications

References 30 publications

Cutaneous malignancies in chronic lymphocytic leukemia

Cutaneous malignancies in chronic lymphocytic leukemia

A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors

Contact Info

Product

Resources

About